A61K 51/1054
The tumor cell being from lung
Official title: {the tumor cell being from lung}
A61K51/1054 (The tumor cell being from lung) appears on 28 US grants and 43 published applications in this corpus.
Search patents in A61K- Granted patents
- 28
- Published applications
- 43
- Assignees
- 32
- Inventors
- 118
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 2 |
| 2006 | 0 | 2 |
| 2007 | 0 | 2 |
| 2008 | 1 | 1 |
| 2009 | 3 | 7 |
| 2010 | 0 | 2 |
| 2011 | 2 | 1 |
| 2012 | 3 | 2 |
| 2013 | 1 | 2 |
| 2014 | 1 | 1 |
| 2015 | 1 | 2 |
| 2016 | 1 | 2 |
| 2017 | 2 | 0 |
| 2018 | 0 | 2 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 3 |
| 2022 | 2 | 3 |
| 2023 | 0 | 1 |
| 2024 | 2 | 3 |
| 2025 | 1 | 2 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Urokinase plasminogen activator receptor-targeted radiopharmaceutical22 Sep 2026US 12,741,039 B2Monopar Therapeutics Inc.
- Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex1 Jul 2025US 12,344,675 B2Abdera Therapeutics Inc.
- Conjugated biological molecules, pharmaceutical compositions and methods17 Sep 2024US 12,090,212 B2Obi Pharma, Inc.
- Anti-mesothelin polypeptide, and tumor imaging agents and complexes thereof7 May 2024US 11,975,080 B2National University Corporation Okayama University
- N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy16 Aug 2022US 11,413,354 B2Memorial Sloan Kettering Cancer Center
- Vhh antibody conjugates with heteroaryl chelators2 Jul 2026US 2026/0183437 A1Abdera Therapeutics Inc.
- Humanized antibody that binds to heg1 protein and complex of antibody and radionuclide20 Mar 2025US 2025/0090700 A1Kanagawa Prefectural Hospital Organization
- Dll3 binding molecules and uses thereof13 Feb 2025US 2025/0051476 A1Abdera Therapeutics Inc.
- Anti-dll3 antibodies and uses thereof7 Nov 2024US 2024/0368269 A1Memorial Hospital for Cancer and Allied Diseases
- Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof22 Aug 2024US 2024/0277878 A1Bristol-Myers Squibb Company
Most cited
By later US patents
- Functionally specific antibodies57US 4,867,962 ANeoRx Corporation · 1989
- Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods55US 5,367,080 ASterling Winthrop Inc. · 1994
- Antibodies and related molecules that bind to PSCA proteins29US 7,595,379 B2Agensys, Inc. · 2009
- Antibodies and related molecules that bind to PSCA proteins24US 8,013,128 B2Agensys, Inc. · 2011
- Antibodies and related molecules that bind to PSCA proteins21US 7,541,442 B2Agensys, Inc. · 2009